These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31570447)

  • 1. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.
    Kang SH; Hwang HJ; Yoo JW; Kim H; Choi ES; Hwang SH; Cho YU; Jang S; Park CJ; Im HJ; Seo JJ; Kim N; Koh KN
    Anticancer Res; 2019 Oct; 39(10):5531-5539. PubMed ID: 31570447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
    Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles.
    Antohe I; Dǎscǎlescu A; Dǎnǎilǎ C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Pavel M; Cianga P
    Front Oncol; 2020; 10():264. PubMed ID: 32231996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.
    Hamdan SO; Sughayer M; Khader M; Tbakhi A; Khudirat S; Hejazi A; AlRyalat S; Bustami N; Aladily TN
    Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
    Greiner J; Götz M; Hofmann S; Schrezenmeier H; Wiesneth M; Bullinger L; Döhner H; Schneider V
    Cancer Immunol Immunother; 2020 Apr; 69(4):629-640. PubMed ID: 32020256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
    Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
    Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
    Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
    J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
    Soo RA; Kim HR; Asuncion BR; Fazreen Z; Omar MFM; Herrera MC; Yun Lim JS; Sia G; Soong R; Cho BC
    Lung Cancer; 2017 Mar; 105():17-22. PubMed ID: 28236980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.
    Berthon C; Driss V; Liu J; Kuranda K; Leleu X; Jouy N; Hetuin D; Quesnel B
    Cancer Immunol Immunother; 2010 Dec; 59(12):1839-49. PubMed ID: 20814675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
    Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
    Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher frequency of the CTLA-4
    Chen Y; Tan J; Huang S; Huang X; Huang J; Chen J; Yu Z; Lu Y; Weng J; Du X; Li Y; Zha X; Chen S
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e12-e18. PubMed ID: 31612643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.
    Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
    Eur J Haematol; 2016 Dec; 97(6):517-527. PubMed ID: 27096305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
    Poh SL; Linn YC
    Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression patterns of immune checkpoints in acute myeloid leukemia.
    Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
    J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
    Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
    Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.
    Onishi A; Fuji S; Kitano S; Maeshima AM; Tajima K; Yamaguchi J; Kawashima I; Kawajiri A; Takemura T; Ito A; Tanaka T; Okinaka K; Inamoto Y; Kurosawa S; Kim SW; Munakata W; Maruyama D; Tobinai K; Fukuda T
    Ann Hematol; 2022 Apr; 101(4):799-810. PubMed ID: 35032188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.